GIGAGEN

In News

GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B - Contagion Live

Contagion Live - Nov 25, 2024

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant - GlobeNewswire

GlobeNewswire - Oct 03, 2024

Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger - Fierce Biotech

Fierce Biotech - Feb 10, 2025

GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment - Clinical Trials Arena

Clinical Trials Arena - Nov 20, 2024

GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development - Yahoo Finance

Yahoo Finance - May 19, 2022

Unleashing the potential of lab-grown recombinant polyclonal antibodies - Drug Target Review

Drug Target Review - Jul 17, 2024

Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug - UW–Madison News

UW–Madison News - Sep 09, 2020

Peninsula biotech reels in potential $135 million contract to be first line of treatment against bioterrorism - The Business Journals

The Business Journals - Oct 03, 2024

GigaGen's New Contract with BARDA for Polyclonal Antibody Development - Contagion Live

Contagion Live - Oct 04, 2024

Recombinant polyclonal antibodies for viral diseases - Drug Discovery News

Drug Discovery News - Mar 25, 2024

Grifols' GigaGen garners up to $135M from BARDA to tackle botulinum biothreat - Fierce Biotech

Fierce Biotech - Oct 03, 2024

GigaGen doses first subject in Phase I advanced solid tumour trial - Clinical Trials Arena

Clinical Trials Arena - May 21, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment